Updates on the clinical trials in diabetic macular edema

Sibel Demirel, Colby Argo, Aniruddha Agarwal, Jacob Parriott, Yasir Jamal Sepah, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


In this era of evidence.based medicine, significant progress has been made in the field of pharmacotherapeutics for the management of diabetic macular edema. (DME). A. number of landmark clinical trials have provided strong evidence of the safety and efficacy of agents such as anti.vascular endothelial growth factors for the treatment of DME. Decades of clinical research, ranging from the early treatment of diabetic retinopathy study to the present.day randomized clinical trials. (RCTs) testing novel agents, have shifted the goal of therapy from preventing vision loss to ensuring a maximum visual gain. Systematic study designs have provided robust data with an attempt to optimize the treatment regimens including the choice of the agent and timing of therapy. However, due to a number of challenges in the management of DME with approved agents, further studies are needed. For the purpose of this review, an extensive database search in English language was performed to identify prospective, RCTs testing pharmacological agents for DME. In order to acquaint the reader with the most relevant data from these clinical trials, this review focuses on pharmacological agents that are currently approved or have widespread applications in the management of DME. An update on clinical trials presently underway for DME has also been provided.

Original languageEnglish (US)
Pages (from-to)3-12
Number of pages10
JournalMiddle East African Journal of Ophthalmology
Issue number1
StatePublished - Jan 1 2016


  • Aflibercept
  • Bevacizumab
  • Clinical Trials
  • Diabetes Mellitus
  • Diabetic Macular Edema
  • Intravitreal Therapy
  • Ranibizumab
  • Retina
  • Vascular Endothelial Growth Factor

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Updates on the clinical trials in diabetic macular edema'. Together they form a unique fingerprint.

Cite this